Treatment of non-alcoholic steatohepatitis

Bailliere's Best Practice and Research in Clinical Gastroenterology

Volumn 16, Issue 5, 2002, Pages 797-810

  Angulo, Paul ^a   Lindor, Keith D ^a  

^a MAYO CLINIC   (United States)

Author keywords

Diabetes mellitus; Hyperlipidaemia; Insulin resistance; NASH; Non alcoholic fatty liver; Obesity; Treatment; Tumour necrosis factor; Ursodeoxycholic acid

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMIODARONE; BETAINE; CALCIUM CHANNEL BLOCKING AGENT; CLOFIBRATE; COCAINE; DIDANOSINE; ESTROGEN; FIALURIDINE; GEMFIBROZIL; GLUCOCORTICOID; GLUCOSE; LIPID; METFORMIN; METHOTREXATE; ORGANIC SOLVENT; PENTOXIFYLLINE; PERHEXILINE MALEATE; PHOSPHORUS; SILYMARIN; TAMOXIFEN; TETRACYCLINE; TROGLITAZONE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VALPROIC ACID; ZIDOVUDINE; METRONIDAZOLE; POLYMYXIN B;

ALCOHOL CONSUMPTION; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE COURSE; EXERCISE; FATTY LIVER; FOLLOW UP; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SURGERY; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LOW CALORY DIET; METABOLIC DISORDER; OBESITY; PATHOGENESIS; PATIENT CARE; PILOT STUDY; PROTEIN CALORIE MALNUTRITION; REVIEW; RISK ASSESSMENT; STARVATION; TOTAL PARENTERAL NUTRITION; TREATMENT INDICATION; TREATMENT OUTCOME; WEIGHT REDUCTION; CLINICAL TRIAL; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; LIPID BLOOD LEVEL; LIVER BIOPSY; LOW FAT DIET; NONALCOHOLIC FATTY LIVER; NONHUMAN; STEATOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR;

DIABETES MELLITUS, TYPE 2; FATTY LIVER; HUMANS; HYPERLIPIDEMIAS; OBESITY; RISK FACTORS;

EID: 0036781495     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1053/bega.2002.0327     Document Type: Article

References (65)

1. Ludwig J Viggiano R T McGill D B Nonalcoholic steatohepatitis: Mayo Clinic experience with a hitherto unnamed disease Mayo Clinic Proceedings 55 1980 342-348
2. Schaffner F Thaler H Nonalcoholic fatty liver disease Progress in Liver Disease 8 1986 283-286
3. Lee R G Nonalcoholic steatohepatitis. A study of 49 patients Human Pathology 20 1989 594-599
4. Powell E E Cooksley W G Hanson R et al. The natural history of nonalcoholic steatohepatitis: a follow up study of forty-two patients for up to 21 years Hepatology 11 1990 74-80
5. Bacon B R Farahvash M J Janney C G Neuschwander-Tetri B A Nonalcoholic steatohepatitis: an expanded clinical entity Gastroenterology 107 1994 1103-1109
6. Teli M Oliver F W Burt A D et al.The natural history of nonalcoholic fatty liver: a follow up study Hepatology 22 1995 1714-1717
7. Matteoni C A Younossi Z M Gramlich T L et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity Gastroenterology 116 1999 1413-1419
8. Ratziu V Giral P Charlotte F et al. Liver fibrosis in overweight patients Gastroenterology 118 2000 1117-1123
9. Angulo P Keach J C Batts K P Lindor K D Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis Hepatology 30 1999 1356-1362
10. Diehl A M Goodman Z Ishak K G Alcohol-like liver disease in nonalcoholic. A clinical and histological comparison with alcohol-induced liver injury Gastroenterology 95 1989 1056-1060
11. Eriksson S Eriksson K F Bondesson L Nonalcoholic steatohepatitis in obesity: a reversible condition Acta Medica Scandinavica 220 1986 83-88
12. Rozental P Biava C Spencer H et al. Liver morphology and function tests in obesity and during total starvation American Journal of Digestive Diseases 12 1967 198-208
13. Drenick E J Simmons F Murphy J Effect on hepatic morphology of treatment of obesity by fasting, reducing diets, and small bowel bypass New England Journal of Medicine 282 1970 829-834
14. Palmer M Schaffner F Effect of weight reduction on hepatic abnormalities in overweight patients Gastroenterology 99 1990 1408-1413
15. Andersen T Gluud C Franzmann M B et al. Hepatic effects of dietary weight loss in morbidly obese patients Journal of Hepatology 12 1991 224-229
16. Ueno T Sugawara H Sujaku K et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver Journal of Hepatology 27 1997 103-107
17. Vajro P Fontanella A Perna C et al. Persistent hyperaminotransferasemia resolving after weight reduction in obese children Journal of Pediatrics 125 1994 239-241
18. Franzese A Vajro P Argenziano A et al. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population Digestive Diseases and Sciences 42 1997 1428-1432
19. Rashid M Roberts E Nonalcoholic steatohepatitis in children Journal of Pediatric Gastroenterology and Nutrition 30 2000 48-53
20. Kanders B S Blackburn G L Very-low-calorie diets for the treatment of obesity In Blackburn G L & Kanders B S (eds) Obesity: Pathophysiology, Psychology and Treatment 1994 197-215 Chapman and Hall New York
21. Kolanowski J A risk-benefit assessment of anti-obesity drugs Drug Safety 20 1999 119-131
22. Abenhaim L Moride Y Brenot F et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension New England Journal of Medicine 335 1996 609-616
23. DeWind L T Payne J H Intestinal bypass surgery for morbid obesity. Long term results Journal of the American Medical Association 236 1976 2298-2301
24. Campbell J M Hung T K Karam J H et al. Jejunoileal bypass as a treatment of morbid obesity Archives of Internal Medicine 137 1977 602-610
25. Ackerman N B Protein supplementation in the management of degenerating liver function after jejunoileal bypass Surgery Gynecology and Obstetrics 149 1979 8-14
26. Drenick E J Fisler J Johnson D Hepatic steatosis after intestinal bypass. Prevention and reversal by metronidazol, irrespective of protein-calorie malnutrition Gastroenterology 82 1982 535-548
27. Buchman A L Dubin M Jenden D et al. Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition in rats Gastroenterology 102 1992 1363-1370
28. Buchman A L Dubin M D Moukarzel A A et al. Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation Hepatology 22 1995 1390-1403
29. Pappo I Becovier H Berry E M et al. Polymixin B reduces cecal flora, TNF production and hepatic steatosis during total parenteral nutrition in rat Journal of Surgical Research 51 1991 106-112
30. Freud H R Muggia-Sullan M LaFrance R et al. A possible beneficial effect of metronidazol in reducing TPN-associated liver function derangements Journal of Surgical Research 38 1985 356-363
31. Lin H Z Yang S Q Chuckaree C et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice Nature Medicine 6 2000 998-1003
32. Assy N Kaita K Mymin D et al. Fatty infiltration of liver in hyperlipidemic patients Digestive Diseases and Sciences 45 2000 1929-1934
33. Laurin J Lindor K D Crippin J S et al. Ursodeoxycholic acid or clofibrate in the treatment of nonalcohol-induced steatohepatitis: a pilot study Hepatology 23 1996 1464-1467
34. Basaranoglu M Acbay O Sonsuz A A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis Journal of Hepatology 31 1999 384
35. Guma G Viola L Thome M et al. Ursodeoxycholic acid in the treatment of nonalcoholic steatohepatitis: results of a prospective clinical controlled trial Hepatology 26 1997 387A
36. Ceriani R Bunati S Morini L et al. Effect of ursodeoxycholic acid plus diet in patients with non-alcoholic steatohepatitis Hepatology 28 1998 386A
37. Holoman J Glasa J Kasar J et al. Serum markers of liver fibrosis in patients with non-alcoholic steatohepatitis (NASH). Correlation to liver morphology and effect of therapy Journal of Hepatology 32 2000 210
38. Barak A J Beckenhauer H C Junnila M et al. Dietary betaine promotes generation of hepatitic S-adenosylmethionine and protects the liver from ethanol-induced fatty infiltration Alcohol Clinical and Experimental Research 17 1993 552-555
39. Abdelmalek M Angulo P Jorgensen R A et al. Betaine a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study American Journal of Gastroenterology 96 2001 2711-2717
40. Gulbahar O Karasu Z A Ersoz G et al. Treatment of non-alcoholic steatohepatitis with N-acetylcysteine Gastroenterology 118 2000 A1444
41. Hasegawa T Yoneda M Nakamura K et al. Long- and short-term d-alpha-tocopherol supplementation inhibits liver collagen alpha-1(I) gene expression Hepatology 26 1997 250A
42. Lavine J E et al. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study Journal of Pediatrics 136 2000 734-738
43. Hasegawa T Yoneda M Nakamura K et al. Plasma transforming growth factor-β1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study Alimentary Pharmacology and Therapeutics 15 2001 1667-1672
44. Angulo P Lindor K D Insulin resistance and mitochondrial abnormalities in NASH: a cool look into a burning issue Gastroenterology 120 2001 1281-1285
45. Day C Thiazolidinediones: a new class of antidiabetic drugs Diabetic Medicine 16 1999 179-192
46. Caldwell S H Hespenheiden E E Redick J A et al. A pilot study of thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis American Journal of Gastroenterology 96 2001 519-525
47. Watkins P B Whitcomb R W Hepatic dysfunction associated with troglitazone New England Journal of Medicine 338 1998 908-909
48. Marchesini G Brizi M Bianchi G et al. Metformin in non-alcoholic steatohepatitis Lancet 358 2001 893-894
49. Letterson P Fromenty B Terris B et al. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice Journal of Hepatology 24 1996 200-208
50. Jaeschke H Wang Y Essani N A Reactive oxygen species activate the transcription factor NF-kB in the liver by induction of lipid peroxidation Hepatology 24 1996 238A
51. Acosta D Wenzel D G Injury produced by free fatty acids to lysosomes and mitochondria in cultured heart muscle and endothelial cells Atherosclerosis 20 1974 417-426
52. Weltman M D Farrell G C Liddle C Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation Gastroenterology 111 1996 1645-1653
53. Weltman M D Farrel G C Hall P et al. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis Hepatology 27 1998 128-133
54. Schuppan D Jia J D Brinkhaus B Hahn E G Herbal products for liver diseases. A therapeutic challenge for the new millennium Hepatology 30 1999 1099-1104
55. Yang S Q Lin H Z Lane M D et al. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis Proceedings of the National Academy of Sciences of the USA 94 1997 2557-2562
56. Chavin K D Yang S Q Lin H Z et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion Journal of Biological Chemistry 274 1999 5692-5700
57. Cortez-Pinto H Chatham J Chacko V P et al. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis. A pilot study Journal of the American Medical Association 282 1999 1659-1664
58. Leclercq I A Farrell G C Field J et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis Journal of Clinical Investigation 105 2000 1067-1075
59. George D K Goldwurm S MacDonald G A et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis Gastroenterology 114 1998 311-318
60. Boncovsky H L Jawaid Q Tortorelli K et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis Journal of Hepatology 31 1999 421-429
61. Younossi Z M Gramlich T Bacon B R et al. Hepatic iron and nonalcoholic fatty liver disease Hepatology 30 1999 847-850
62. Desai T K Phlebotomy reduces transaminase levels in patients with non-alcoholic steatohepatitis Gastroenterology 118 2000 A975
63. Nitecki J Jackson F W Allen M L et al. Effect of phlebotomy on non-alcoholic steatohepatitis (NASH) Gastroenterology 118 2000 A1474 (Abstract)
64. Charlton M Kasparova P Weston S et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease Liver Transplantation 7 2001 608-614
65. Contos M J Cales W Sterling R K et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis Liver Transplantation 7 2001 363-373